GeoVax Labs announces Phase 2 plans for Gedeptin cancer therapy

GeoVax Labs announced the next steps for the clinical development of its Gedeptin cancer therapy, following a clinical advisory committee review. GeoVax and a specially convened clinical advisory committee have completed a comprehensive review of the recently completed PNP-002 Phase 1b/2a trial, together with the previously completed PNP-001 Phase 1 trial. The Phase 1b/2a trial evaluated the safety and efficacy of repeat cycles of Gedeptin therapy in patients with advanced head and neck squamous cell carcinoma, with tumor(s) accessible for injection and no curable treatment options.